TITAN Blend (Tesamorelin / CJC-1295 / Ipamorelin / BPC-157): What It Is, Where to Get It Prescribed, and What It Costs

TITAN is not a single molecule. It is four independently studied peptides dissolved together in one sterile multi-dose vial by a compounding pharmacy. Three of them — tesamorelin, CJC-1295 and ipamorelin — prompt the pituitary to release the body's own growth hormone. The fourth, BPC-157, has nothing to do with the growth hormone axis; it is a repair peptide with its own, separate literature. Each has its own described mechanism and its own regulatory file at the FDA. The name is a brand name for the combination; it does not appear in any journal. That shapes everything on this page: "does TITAN work" has to be broken into four questions, because the combination itself has never been studied as a combination.

The rationale prescribers give has two halves. The pituitary releases growth hormone in pulses when it receives two signals at once: GHRH, and a ghrelin-receptor signal. Tesamorelin and CJC-1295 both supply the first; ipamorelin supplies the second. That is the same three-secretagogue core as the ASCEND blend. The second half is BPC-157, added on the reasoning that someone whose goal is recovery — from training, from a nagging tendon, from a gut that complains — wants a repair signal running alongside the hormonal one rather than a further push on the same axis.

The proportions are worth noticing. Ipamorelin is 12 of the 38 mg in the vial, tesamorelin and BPC-157 10 each, and CJC-1295 6. At the standard 0.25 mL dose that is 0.6 mg ipamorelin, 0.5 mg tesamorelin, 0.5 mg BPC-157 and 0.3 mg CJC-1295. The ratio is fixed by the pharmacy's formulation and cannot be adjusted per component, which matters here because the four have very different amounts of human data behind them.

It is not growth hormone: nothing in the vial is somatropin, and three of the four components only work if your own pituitary responds. It is not a weight-loss medication; the one component with human trials, tesamorelin, carries a label statement that its effect on body weight is neutral. It is not an anabolic steroid. It is not a painkiller, and it is not a treatment for a structural problem — a full-thickness tendon rupture or a displaced fracture is a surgical question, and no peptide changes that. And it is not a substitute for training, sleep or protein intake: every component is described as supporting a process the body is already running, not as creating one.

Tesamorelin is the full 44-amino-acid sequence of growth-hormone-releasing hormone with a trans-3-hexenoic acid group on one end that protects it from the enzyme DPP-4, which otherwise cuts native GHRH apart within minutes. It binds the GHRH receptor on pituitary somatotroph cells and triggers a pulsatile growth hormone release that remains subject to somatostatin, the body's brake signal. In the 2007 New England Journal of Medicine trial, IGF-1 — the liver-made growth factor through which growth hormone does most of its work — rose by 81 percent over 26 weeks. Growth hormone is lipolytic, and visceral fat carries a higher density of the relevant receptors than subcutaneous fat, which is the mechanistic reason every tesamorelin trial has reported the same pattern: a measurable reduction in visceral fat on CT with no significant change in subcutaneous fat. A fuller treatment is on the tesamorelin page.

CJC-1295 is a 29-amino-acid analogue of GHRH with four substitutions that protect it from DPP-4, the enzyme that clears sermorelin and native GHRH. It binds the same pituitary receptor as tesamorelin and drives both release of stored growth hormone and synthesis of more. The form in TITAN is CJC-1295 without the drug affinity complex, so it is cleared within the hour and is dosed nightly. A 2006 paper in the Journal of Clinical Endocrinology and Metabolism sampled blood every ten minutes in healthy adults given the DAC form and reported that the pituitary's pulsatile pattern was preserved, with more growth hormone per pulse rather than a flat elevation — the basis for describing secretagogues as working with the axis rather than overriding it. Because it shares tesamorelin's receptor, the pairing is about dose and duration rather than a new mechanism. See CJC-1295 / Ipamorelin.

Ipamorelin is a pentapeptide that binds the growth hormone secretagogue receptor, GHS-R1a, on pituitary cells and in the hypothalamus. It triggers growth hormone release directly and is described as reducing somatostatin at the hypothalamus. The 1998 characterisation paper in the European Journal of Endocrinology reported that in animal models it released growth hormone with potency similar to GHRP-6 but, unlike GHRP-6 and GHRP-2, did not raise ACTH, cortisol or prolactin at doses well above the releasing dose. That selectivity is why it is the ghrelin-receptor agonist in prescribing blends, and why it is paired with a GHRH analogue: two different signals converging on the same pulse. Its own page is ipamorelin.

BPC-157 is a fifteen-amino-acid partial sequence of a protein originally isolated from human gastric juice. Animal work describes it activating the VEGFR2 receptor and downstream nitric-oxide signalling, which is the axis the body uses to grow new blood vessels into healing tissue. A 2011 paper in the Journal of Applied Physiology reported that in a rat Achilles tendon model it promoted tendon outgrowth, cell survival and cell migration, and a 2014 paper in Molecules reported that it increased growth hormone receptor expression in cultured tendon fibroblasts. That second finding is the reason BPC-157 sits in a growth-hormone blend at all, and it is often misread: it describes making those particular cells more responsive to growth hormone already present, not raising growth hormone. The largest body of BPC-157 research concerns protection of the gastrointestinal lining in animal models, reviewed in Current Pharmaceutical Design in 2018, which is where the compound was first identified. A fuller treatment is on the BPC-157 page.

The map below is the clinical rationale for the blend. It is a rationale, not a finding — no study has confirmed that the four act as described when injected together.

The last row is the one link between the two halves, and it rests on a cell-culture finding. Nobody has measured whether raising growth hormone and adding BPC-157 in the same person does more than either alone.

This is the component with real human trials. The 2007 New England Journal of Medicine trial randomised 412 people with HIV and abdominal fat accumulation to daily tesamorelin 2 mg or placebo for 26 weeks: visceral fat on CT fell 15.2 percent on treatment and rose 5.0 percent on placebo, triglycerides fell, and glycaemic measures did not differ. A 2010 pooled analysis in the Journal of Clinical Endocrinology and Metabolism covered 806 randomised patients across two phase 3 trials, reporting a treatment effect of −15.4 percent on visceral fat, no significant change in subcutaneous fat, and visceral fat returning toward baseline in those switched to placebo. A 2014 trial in JAMA in 50 people with HIV reported a reduction in visceral fat and a modest reduction in liver fat over six months. Every trial used a fixed daily dose of 1 or 2 mg in a defined population; none used the 0.5 mg five nights a week delivered by TITAN, and none combined it with other peptides.

The human evidence is two 2006 studies in the Journal of Clinical Endocrinology and Metabolism, both of the DAC form in healthy adults. The first reported dose-dependent increases in growth hormone and IGF-1 that persisted for days after a single injection and were described as well tolerated; the second is the pulsatility study above. None of this measured body composition, recovery or sleep, and none used the non-DAC form at a nightly dose.

A 1999 paper in Pharmaceutical Research modelled the growth hormone response to intravenous ipamorelin in human volunteers and reported dose-dependent release with a half-life measured in hours. A 2014 randomised, placebo-controlled phase 2 study in the International Journal of Colorectal Disease of intravenous ipamorelin for post-operative ileus in bowel-resection patients did not show a significant difference from placebo — the largest human study of ipamorelin, at a different route, dose and population from anything on this page.

Tendon and ligament is the strongest area, and it is animal and cell work: the 2011 rat Achilles study and the 2014 tendon-fibroblast study above, alongside earlier rat work reporting faster reattachment of a detached Achilles tendon. Animal models of muscle crush injury report faster functional recovery in the animal. The gastrointestinal literature is the deepest: animal work describing protection against NSAID- and alcohol-induced gastric damage and improvement in inflammatory bowel models. Early-phase human work has been conducted for inflammatory bowel indications. There are no large randomised controlled trials of BPC-157 in humans, and none for tendon or soft-tissue injury.

The rationale is physiological: the largest growth hormone pulse of the day occurs during slow-wave sleep, and both are reported to decline together with age in healthy men. Patients frequently report deeper sleep on bedtime secretagogues. No published trial of any component, let alone the blend, has sleep or recovery as an endpoint.

This is the honest part, and the part worth understanding before starting.

There are no randomised controlled trials of TITAN, or of any four-peptide combination of these components, in humans. The blend has never been studied as a blend. Evidence is per component, and it is uneven:

• Tesamorelin has randomised, double-blind, placebo-controlled trials, including two phase 3 trials that supported an FDA approval — a materially stronger base than any other compounded growth-hormone secretagogue.
• CJC-1295 has small studies in healthy adults, of the DAC form, showing it raises growth hormone and IGF-1. No trial has measured a clinical outcome.
• Ipamorelin has pharmacokinetic work in volunteers and one randomised phase 2 trial, for post-operative ileus, that did not meet its endpoints.
• BPC-157 has early-phase human work for inflammatory bowel indications and substantial prescribing experience. There are no large randomised controlled trials in humans, and none for tendon or soft-tissue injury.

Much of medicine rests on mechanism plus clinical experience, and that is the basis physicians prescribe TITAN on. But the accurate framing is "three components known to raise growth hormone or IGF-1 in humans, one studied in animals and cells and used clinically, combined on a physiological rationale," not "proven for recovery or body composition."

• That four peptides together do more than any one alone. No study has compared the blend with its components, and no study has tested a growth-hormone secretagogue and BPC-157 in the same person.
• An effect on muscle size, strength, athletic performance or scale weight in humans. Tesamorelin's trials measured visceral fat on CT and its label calls it weight-neutral; BPC-157's muscle findings are animal.
• Results at TITAN's doses. The tesamorelin data is at 1–2 mg daily; 0.5 mg five nights a week is a physician's extrapolation.
• An effect size or a timeline in humans. Timelines given by prescribers are clinical experience, not trial endpoints.
• Long-term safety over years of continuous use, which is why IGF-1 and fasting glucose are monitored and why a physician reviews each refill.
• Efficacy for any condition as an FDA-approved treatment. TITAN is not approved for anything; tesamorelin's approval belongs to a different product at a different dose for a specific population.

Egrifta (tesamorelin acetate) was approved on 10 November 2010 under NDA 022505, sponsored by Theratechnologies, and on 23 March 2020 that approval was deemed a biologics licence in the transition that moved protein products onto the Purple Book. The current formulation, Egrifta WR, is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy and is dosed at 1.28 mg once daily. Its label, revised March 2025, carries three limitations of use — long-term cardiovascular safety has not been established, it is not indicated for weight-loss management because its effect on weight is neutral, and there are no data to support improved antiretroviral compliance — and is contraindicated in active malignancy, pregnancy, known hypersensitivity, and disruption of the hypothalamic-pituitary axis. It also directs that IGF-1 be monitored during therapy and glucose evaluated before and during it.

Because it is the active ingredient of an approved product, tesamorelin was never nominated for the 503A bulks list, is not in Category 1, 2 or 3 of the list as updated 14 May 2026, and did not move in the 2026 changes. Compounded tesamorelin is not Egrifta: it has not been reviewed by the FDA for safety, effectiveness or manufacturing quality as a finished product, and the trial data belongs to the approved product at its approved doses. Prescribing it for anything other than HIV-associated lipodystrophy is off-label, which is a physician's decision and common across medicine, but should be understood as such.

Both were placed in Category 2 of the FDA's interim 503A bulk drug substances list in September 2023, the category for substances flagged as raising significant safety concerns, and both were then taken through the FDA's Pharmacy Compounding Advisory Committee in full.

On 29 October 2024 the committee considered ipamorelin, evaluated for growth hormone deficiency and post-operative ileus, and voted 0 yes, 12 no, 1 abstain against recommending both the free base and the acetate for the 503A Bulks List, with members who voted no citing a lack of information supporting safety and efficacy for those two uses. On 4 December 2024 the committee considered the CJC-1295 family, evaluated for growth hormone deficiency, and voted 0–13 against CJC-1295 free base and 1–12 against CJC-1295 acetate; the three DAC forms were voted against 0–13 each.

Both have since left the 503A Category 2 list. The list as updated 14 May 2026 has six substances in Category 2, and neither CJC-1295 nor ipamorelin appears in Category 1, 2 or 3. The FDA's safety-risks page, current as of 22 April 2026, lists CJC-1295 among substances "nominated but withdrawn," with the agency's stated concerns being immunogenicity risk for certain routes, peptide-related impurities, and reports of increased heart rate and a vasodilatory reaction; ipamorelin acetate is likewise withdrawn for 503A pharmacies, which is what compounds to an individual prescription, but remains listed in Category 2 for 503B outsourcing facilities. Neither was on the agenda of the 23–24 July 2026 committee meeting.

The committee evaluates a substance for the specific uses in its nomination against the FDA-approved drugs that already exist for them; a vote against is not a finding that the peptide is unsafe at prescribed doses, and it is not a ban. The FDA has not issued a final determination on either. Both are prescribed by physicians and compounded by licensed 503A pharmacies to those prescriptions.

BPC-157 was placed in Category 2 in September 2023. In April 2026 the FDA removed it from Category 2, along with eleven other peptides; the safety-risks page, current as of 22 April 2026, now lists it among substances "nominated but withdrawn," with the agency's stated concern being possible immunogenicity for certain routes and limited safety information, and the 14 May 2026 list shows it in no category at all.

On 23 July 2026 the Pharmacy Compounding Advisory Committee took separate votes on BPC-157 free base and BPC-157 acetate for the 503A Bulks List, evaluated for ulcerative colitis, and voted 8–6 to recommend adding it. FDA's own scientists had recommended against inclusion; the committee weighed the presentations and voted the other way. A committee vote is a recommendation, not a decision. The FDA issues its own determination through rulemaking, and that determination is still pending as of September 2026.

None of the four components is currently in 503A Category 2. One is the active ingredient of an approved biologic, prescribed off-label in this blend. Two were recommended against by the advisory committee in late 2024 for the specific uses in their nominations, with no final FDA rule issued. One was recommended for the positive list in July 2026 and awaits the FDA's final action. TITAN itself is not an FDA-approved drug product, and compounded medications never are — they are prepared by a licensed pharmacy to a physician's prescription, not approved as manufactured products. See are peptides FDA approved.

Most of what is reported early is about sleep: some people describe falling asleep faster or sleeping more deeply within the first few nights of bedtime dosing, consistent with the timing of the growth hormone pulse but not measured in any trial. Injection-site tenderness, hunger after the dose and a brief flush are the other early observations. Noticing nothing in this window is normal and is not a sign the course is not working.

This is where prescribers describe recovery between training sessions feeling shorter and a reduced background ache in an injured area, where those happen. It is also the window in which the follow-up IGF-1 measurement tells your physician whether the pituitary is responding and whether the dose is right — the number, rather than how you feel, is what the dose is titrated against. For tissue-level change in a tendon, this is the window the animal timelines point to, and it typically takes a second vial to reach.

Visceral fat change in the tesamorelin trials was measured at 26 weeks. Prescribers who use TITAN with body composition as a goal describe it as a months-long proposition alongside training and diet. Chronic tendon problems are described as needing longer than a recent acute injury. Nothing produces visible change in two weeks.

No withdrawal and no rebound are described for any component. Because the three secretagogues work through your own pituitary, output returns to its baseline pattern when they stop; the tesamorelin extension data, in which visceral fat returned toward baseline on placebo, is the clearest demonstration that the measured effect does not persist on its own. Whether any benefit from the BPC-157 side persists depends on whether the underlying tissue actually changed.

The directions are written in millilitres and in insulin-syringe units because that is what you can actually read off the barrel. 0.25 mL is 25 units on a U-100 syringe. You are not calculating anything — the number is printed on your medication. Because the four are in fixed proportion, every dose delivers the same split; you cannot take more of one and less of another. If your directions and syringe markings appear to disagree, ask before dosing.

Subcutaneous means into the fat layer, not the muscle. Abdomen and thigh are the usual sites, rotated so the same spot is not used repeatedly. Bedtime is specified because the body's largest growth hormone pulse occurs in the first hours of sleep and the secretagogues are meant to reinforce it. Prescribers generally direct that the dose be taken away from food, because a rise in blood glucose and insulin blunts growth hormone release. Your directions will say.

20 doses at five per week is four weeks of weekday dosing, which is why refills run on a monthly cycle. Weekends off is part of the schedule, not a missed dose. One vial per fill, always — not a stockpile.

Refrigerated, and it ships that way in insulated packaging with ice packs. Beyond-use dating runs from first puncture and is on the label; a four-peptide vial is not something to keep past it.

The two blends share three components at identical amounts and differ in the fourth. ASCEND adds IGF-1 LR3, a modified growth factor acting downstream of growth hormone, which brings its own blood-sugar and growth-signalling cautions and has essentially no human data. TITAN adds BPC-157, a repair peptide acting outside the axis altogether. If the goal is recovery from training or a soft-tissue problem alongside a restored growth hormone pulse, TITAN is the more usual choice, and it is the one without the IGF-1 LR3 questions.

The two-peptide CJC-1295 / Ipamorelin blend is the secretagogue core of TITAN without tesamorelin or BPC-157. It is the more common starting prescription for sleep and recovery, it is available as a Pen, and it is the simpler thing to evaluate on a first course. Whether TITAN's additions are wanted is a physician's judgement about the goal.

Tesamorelin on its own delivers the one component with phase 3 evidence, at a higher dose per injection and with a simpler safety file; if the goal is specifically visceral fat, it is the more evidence-based prescription. BPC-157 on its own delivers the repair component at the same 0.5 mg per injection, dosed daily rather than five days a week, without the bloodwork the growth-hormone axis requires. TITAN is supplied as a vial and syringe only; there is no Pen cartridge for this blend.